| Trial ID | NCT06395389 |
| Status | Recruiting |
| Condition | Cannabis Use Disorder |
| Intervention | Health Education (HealthEdu) |
Cannabis use disorder affects nearly 3 million emerging adults annually, yet evidence-based brief interventions remain limited for this critical developmental period. This trial addresses a significant gap in scalable, age-appropriate cannabis treatment options when early intervention could prevent progression to severe dependency.
This randomized controlled trial compares two brief interventions for potentially problematic cannabis use in emerging adults aged 18-25. The study employs a rigorous design with two 40-50 minute sessions separated by one week, followed by assessments at post-intervention, 1-month, and 3-month intervals. Biological validation through salivary THC and CBD testing accompanies self-report measures at all four timepoints. The trial is currently recruiting participants for this Phase II behavioral intervention study.
“If positive, this trial could provide me with evidence-based brief intervention protocols specifically validated for emerging adults with cannabis use concerns. Having structured, time-limited interventions with demonstrated efficacy would significantly enhance my ability to offer targeted early intervention before patterns become entrenched.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Who is this brief cannabis intervention trial designed for?
The trial is designed for emerging adults aged 18 to 25 with potentially problematic cannabis use, and the condition listed is cannabis use disorder. It is a randomized controlled trial that compares two brief interventions, one of which is listed as Health Education (HealthEdu).
How much time does taking part in this trial involve?
Participants attend two sessions of 40 to 50 minutes each, separated by one week. The sessions are followed by assessments right after the intervention, at one month, and at three months, so participation continues for up to three months after the intervention.
How will researchers verify participants’ reported cannabis use?
The trial pairs self-report measures with biological testing. Saliva is tested for THC and CBD at all four assessment timepoints, providing an objective check alongside what participants report about their own cannabis use. The article describes the design as rigorous, and this biological validation is part of it.
Is this cannabis intervention trial still enrolling, and are results available?
The trial, registered as NCT06395389, is listed as currently recruiting participants. It is a Phase II behavioral intervention study, and the article does not report any results, so it is not yet known whether either brief intervention reduces problematic cannabis use in emerging adults.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
